Organon & Co. (NYSE:OGN) Reaches New 1-Year High – Here’s Why

Organon & Co. (NYSE:OGN)’s share price reached a new 52-week high on Monday . The stock traded as high as $13.47 and last traded at $13.4550, with a volume of 536582 shares traded. The stock had previously closed at $13.40.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Zacks Research upgraded shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. BNP Paribas Exane restated a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Wall Street Zen cut shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Weiss Ratings upgraded shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday. Finally, Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $11.40.

Organon & Co. Trading Up 0.1%

The firm has a market cap of $3.53 billion, a P/E ratio of 14.45, a price-to-earnings-growth ratio of 1.24 and a beta of 1.57. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47. The firm’s 50-day simple moving average is $9.02 and its 200 day simple moving average is $8.11.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing the consensus estimate of $0.83 by ($0.12). The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business’s revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 EPS. As a group, analysts expect that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be given a $0.02 dividend. The ex-dividend date of this dividend is Monday, May 11th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s payout ratio is currently 8.60%.

Insider Buying and Selling

In related news, SVP Lynette Holzbaur acquired 26,448 shares of the stock in a transaction on Wednesday, May 6th. The shares were acquired at an average price of $13.35 per share, with a total value of $353,080.80. Following the completion of the transaction, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. The trade was a 100.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.62% of the company’s stock.

Institutional Trading of Organon & Co.

Several hedge funds have recently added to or reduced their stakes in OGN. Royal Bank of Canada raised its position in Organon & Co. by 53.4% in the first quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock worth $5,374,000 after acquiring an additional 125,648 shares during the period. Goldman Sachs Group Inc. raised its position in Organon & Co. by 126.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after acquiring an additional 801,307 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Organon & Co. by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock worth $15,530,000 after acquiring an additional 26,640 shares during the period. Focus Partners Wealth raised its position in shares of Organon & Co. by 33.2% in the first quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock valued at $832,000 after purchasing an additional 13,925 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Organon & Co. in the second quarter valued at approximately $107,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.